drugset / Trial / NCT05182567
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
RandomizedParallel-groupOpen-labelPrevention
Summary
Phase I study to assess the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine given as a booster to those previously vaccinated against SARS-CoV-2
Timeline
- Start
- 2022-05-23
- Primary completion
- 2023-01-10
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLS-5310 | Vaccine | — | Intramuscular |